Key Highlights
- ORIC Pharmaceuticals shares closed up 27.08% at $13.47, after the company reported second-quarter results and pipeline updates.
- The company initiated Himalayas-1, a global Phase 3 registrational trial evaluating rinzimetostat in prostate cancer, expected to enroll roughly 600 patients across 250 sites in 25 countries.
- ORIC entered a clinical trial collaboration with Bayer to provide darolutamide for the Himalayas-1 trial at no cost.
- The company reported a wider-than-expected quarterly loss of $0.38 per share versus a $0.36 consensus, though cash of $387.6 million provides runway into the second half of 2028.
- Investors appear to be rewarding the company's pipeline progress amid broader biotech sector speculation around a potential AstraZeneca-Bristol Myers Squibb tie-up.
What Drove the Close
ORIC Pharmaceuticals (NASDAQ:ORIC) shares surged 27.08% to close at $13.47, with a day range of $10.64 to $13.73 on volume of 4.98 million shares, after the company reported second-quarter financial results and provided operational updates highlighted by the initiation of a pivotal Phase 3 trial.
ORIC Pharmaceuticals is a South San Francisco, California-based clinical-stage biopharmaceutical company dedicated to what it calls Overcoming Resistance In Cancer, developing precision oncology therapies. Its lead clinical-stage candidates include rinzimetostat, an allosteric PRC2 inhibitor for prostate cancer, and enozertinib, a brain-penetrant EGFR inhibitor for non-small cell lung cancer and other genetically defined tumors, alongside earlier-stage programs targeting additional resistance mechanisms.
The company finalized the trial protocol and initiated Himalayas-1, a global Phase 3 registrational trial, following End-of-Phase 1 interactions with the FDA and other global health authorities. The trial is expected to enroll approximately 600 patients from more than 250 sites in 25 countries, randomized to receive rinzimetostat in combination with darolutamide versus physician's choice of an androgen receptor inhibitor or docetaxel, with radiographic progression-free survival as the primary endpoint.
ORIC entered a clinical trial collaboration and supply agreement with Bayer, under which Bayer will provide its androgen receptor inhibitor NUBEQA at no cost for use in the trial, while ORIC retains full global development and commercial rights to rinzimetostat. CEO Jacob Chacko said the initiation of Himalayas-1 brings the company closer to delivering a potentially practice-changing therapy for prostate cancer patients.
Financial Results and Pipeline Outlook
Second-quarter research and development expenses were $36.3 million, up from $30.5 million in the prior-year period, primarily due to increased spending on rinzimetostat's advancement. General and administrative expenses were $9.0 million, up from $8.5 million. Net loss was $41.5 million, or $0.38 per share, compared with a $0.36 consensus estimate, a wider-than-expected loss.
Cash, cash equivalents, and investments totaled $387.6 million as of June 30, which the company expects will fund its operating plan into the second half of 2028, beyond the anticipated primary endpoint readout from the first Phase 3 trial for rinzimetostat. For enozertinib, the company anticipates presenting first-line EGFR atypical monotherapy data at the ESMO Congress in October, with additional exon 20 insertion monotherapy and combination data expected in the second half of 2026.
ORIC's market capitalization stood at $1.39 billion. The stock's 52-week range spans $7.23 to $14.93, with today's close pushing shares to near the top of that range. Investors appear to be rewarding the company's pipeline progress amid a broader wave of biotech and pharma deal speculation, including reports of a potential AstraZeneca-Bristol Myers Squibb tie-up that has kept sector attention elevated.
Conclusion
ORIC Pharmaceuticals' sharp rally reflects investor enthusiasm for the initiation of its pivotal Himalayas-1 trial and the strategic value of its Bayer collaboration, even as the company posted a wider-than-expected quarterly loss. With cash runway extending into the second half of 2028 and enozertinib data expected later this year, the stock's trajectory will likely depend on continued execution across both of its late-stage oncology programs.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.




_11_17_2026_20_37_58_946960.jpg)

Please wait processing your request...